These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 21296603)
1. Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. Li T; Wells G; Westhovens R; Emery P; Becker JC; Tugwell P Value Health; 2011; 14(2):361-70. PubMed ID: 21296603 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472 [TBL] [Abstract][Full Text] [Related]
3. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Li T; Gignac M; Wells G; Shen S; Westhovens R Clin Ther; 2008 Apr; 30(4):734-48. PubMed ID: 18498922 [TBL] [Abstract][Full Text] [Related]
4. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. Wells G; Li T; Tugwell P Ann Rheum Dis; 2010 Oct; 69(10):1768-73. PubMed ID: 20610444 [TBL] [Abstract][Full Text] [Related]
5. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Russell AS; Wallenstein GV; Li T; Martin MC; Maclean R; Blaisdell B; Gajria K; Cole JC; Becker JC; Emery P Ann Rheum Dis; 2007 Feb; 66(2):189-94. PubMed ID: 16984942 [TBL] [Abstract][Full Text] [Related]
6. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491 [TBL] [Abstract][Full Text] [Related]
7. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265 [TBL] [Abstract][Full Text] [Related]
8. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431 [TBL] [Abstract][Full Text] [Related]
9. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865 [TBL] [Abstract][Full Text] [Related]
10. The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIN study. Hassett AL; Li T; Buyske S; Savage SV; Gignac MA Curr Med Res Opin; 2008 May; 24(5):1443-53. PubMed ID: 18402714 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185 [TBL] [Abstract][Full Text] [Related]
12. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499 [TBL] [Abstract][Full Text] [Related]
13. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. Emery P; Kosinski M; Li T; Martin M; Williams GR; Becker JC; Blaisdell B; Ware JE; Birbara C; Russell AS J Rheumatol; 2006 Apr; 33(4):681-9. PubMed ID: 16568505 [TBL] [Abstract][Full Text] [Related]
14. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357 [TBL] [Abstract][Full Text] [Related]
15. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Li T; Ge Z; Becker JC; Westhovens R Ann Intern Med; 2006 Jun; 144(12):865-76. PubMed ID: 16785475 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Dougados M; Schmidely N; Le Bars M; Lafosse C; Schiff M; Smolen JS; Aletaha D; van Riel P; Wells G Ann Rheum Dis; 2009 Apr; 68(4):484-9. PubMed ID: 19074177 [TBL] [Abstract][Full Text] [Related]
17. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Schiff M; Pritchard C; Huffstutter JE; Rodriguez-Valverde V; Durez P; Zhou X; Li T; Bahrt K; Kelly S; Le Bars M; Genovese MC Ann Rheum Dis; 2009 Nov; 68(11):1708-14. PubMed ID: 19074911 [TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774 [TBL] [Abstract][Full Text] [Related]
19. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis. Benucci M; Stam WB; Gilloteau I; Sennfält K; Leclerc A; Maetzel A; Lucioni C Clin Exp Rheumatol; 2013; 31(4):575-83. PubMed ID: 23711100 [TBL] [Abstract][Full Text] [Related]
20. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]